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Rituximab in primary Sjo¨gren’s syndrome: a ten-year journey
F Carubbi1, A Alunno2, P Cipriani1, E Bartoloni2, F Ciccia3, G Triolo3, R Gerli2 and R Giacomelli1
1Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L’Aquila, L’Aquila, Italy; 2Department of
Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy; and 3Department of Internal Medicine, Division of Rheumatology,
University of Palermo, Palermo, Italy
Primary Sjo¨gren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands and
characterized in most cases by a rather mild clinical picture. However, a subgroup of pSS
patients experience systemic extraglandular involvement leading to a worsening of disease
prognosis. Current therapeutic options for the treatment of pSS are mainly empirical, often
translated by other autoimmune diseases, and recent systematic reviews have highlighted the
lack of evidence-based recommendations for most of the drugs commonly employed in the
spectrum of extraglandular involvement. Because of the well-established role of B-lympho-
cytes in the pathogenesis of pSS, a B-cell targeting therapy may represent a new and intriguing
therapeutic approach; in this context, growing evidence suggests that B-cell depletion by
rituximab (RTX) is also effective in pSS. Of interest, besides clinical efficacy, RTX also
showed biologic effects, consistently affecting the inflammation and the lymphoid organiza-
tion that occur in target tissue. Moreover, the good results observed in the published trials
after RTX treatment in pSS should represent the starting point to develop evidence-based
guidelines for the use of biologic therapy in this disease. Lupus (2014) 23, 1337–1349.
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Introduction
Primary Sjo¨gren’s syndrome (pSS) is a chronic sys-
temic autoimmune disease characterized by muco-
sal dryness and, in at least one-third of patients, by
extraglandular involvement, with musculoskeletal,
cutaneous, renal, pulmonary or neurological
manifestations.1
In pSS, both T and B cells contribute to disease
pathogenesis, infiltrating the exocrine glands and
other target tissues, showing evidence of clonal
expansion in the aﬀected tissues as well as in the
circulation.2–6
The therapeutic approach to sicca symptoms
is mainly aimed at reducing the discomfort and
preventing local complications. Topical medica-
tions, including saliva substitutes and eyedrops,
are widely employed as are topical cyclosporine
and/or corticosteroids for refractory keratocon-
junctivitis sicca.7 In patients with a certain degree
of residual glandular function, the employment
of systemic secretagogues such as pilocarpine
and cevimeline should be considered. However,
solid scientific evidence of eﬃcacy is still lacking
and adverse events frequently lead to therapy dis-
continuation.8 Recent systematic reviews have
highlighted the lack of evidence-based recommen-
dations for most of the drugs commonly employed
in the spectrum of extraglandular involvement and,
ultimately, pSS may be still considered an
orphan disease.1,7–10 Besides conventional immuno-
suppressive compounds, eﬃcacy of targeted thera-
pies in other systemic autoimmune diseases such as
rheumatoid arthritis and systemic lupus erythema-
tosus (SLE) have suggested their possible use in
pSS as well. Indeed, the treatment with immuno-
suppressive and biologic agents in pSS is mainly
based on their eﬃcacy in the aforementioned con-
ditions, expert opinion and uncontrolled studies.
Although many clinical manifestations may be
shared among diﬀerent systemic autoimmune dis-
eases, it should be kept in mind that the underlying
pathogenic mechanisms should be diﬀerent. These
data point out the need of randomized clinical trials
(RCTs) to investigate the safety and eﬃcacy of
these drugs in pSS, thus providing solid scientific
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evidence. Taken together, the diﬃculty of building
therapeutic recommendations in pSS may be
related to the heterogeneity of the clinical picture,
the frequent failure of first-line treatments, the lack
of scientific evidence for drugs licensed for other
diseases and, finally, the lack of innovative thera-
peutic compounds.
Growing evidence has pointed out that B cells
play a central role in the development, maintenance
and progression of the disease, with multiple roles at
diﬀerent levels in pSS pathophysiology.11 In particu-
lar, B-lymphocyte hyperactivity, minor salivary
gland (MSG) infiltration and development of
B-cell follicles containing germinal center (GC)-
like structures represent the hallmark of the
disease.12 Although the peculiar role of B cells in
autoimmunity is the production of autoantibodies,
several data suggest that B cells may also exert add-
itional pivotal functions such as antigen presenta-
tion and release of specific cytokines with immune
regulatory, proinflammatory, polarizing and tissue-
organizing functions.13,14 Excessive B-cell activation
is responsible for a number of the extraglandular
manifestations and serological features of pSS,
including hypergammaglobulinemia, cryoglobuline-
mia, elevated levels of free light chains and
b2-microglobulin, presence of autoantibodies to
the autoantigens SSA/Ro and SSB/La, or rheuma-
toid factor (RF), hypocomplementemia, hypergam-
maglobulinemic purpura, arthritis, vasculitis,
neuropathy, and glomerulonephritis.15 Moreover,
prolonged B-cell survival and aberrant B-cell activ-
ity may lead to the development of non-Hodgkin
lymphomas (NHL) in 5% of pSS patients; in these
cases the extranodal marginal zone B-cell lymphoma
of the mucosa-associated lymphoid tissue (MALT)
represents the most common subtype.6,11,16
Because of the well-established role of B lympho-
cytes in the pathogenesis of pSS, a B-cell targeting
therapy may represent a new and intriguing thera-
peutic approach in this disease.
The aim of this review article is to discuss the
currently available literature concerning B-cell
depleting therapy with anti-CD20 monoclonal anti-
body rituximab (RTX) in pSS, separately consider-
ing the two main emerging aspects related to this
treatment, such as the biological and the clinical
eﬀects, and underscoring their reciprocal influence.
Rituximab in pSS: biological effects
RTX is a chimeric murine/human monoclonal
antibody targeting the CD20 molecule (human
B-lymphocyte-restricted diﬀerentiation antigen,
Bp35) found on the surface of most B cells, includ-
ing pre-B and mature B lymphocytes, but not on
stem cells, pro-B-cells, normal plasma cells or other
normal tissues.17 There are at least four postulated
mechanisms of action for RTX: complement-
mediated cytotoxicity, antibody-dependent cell-
mediated cytotoxicity, induction of apoptosis and
saturation of the Fc receptors of eﬀector cells.18
The first prospective, open-label study that inves-
tigated RTX eﬀect in 16 pSS patients showed a
complete B-cell depletion by immunohistochemis-
try in all patients treated with RTX at week 12.19
Subsequently, in 2009, Pijpe et al. reported the first
histological evidence of a reduction in glandular
inflammation, combined with signs of partial glan-
dular restoration in five pSS patients treated with
RTX.20 Following RTX treatment, the lympho-
cytic infiltrate was reduced, showing a decreased
B:T cell ratio with a disappearance of GCs. Of
note, the histological findings paralleled the
increase of parotid salivary flow and the normaliza-
tion of the salivary sodium content, pointing out
that the eﬃcacy of B-cell depletion may also
induce a potential glandular restoration in pSS.
Pers and colleagues analyzed the recovery of B-
cell subsets after RTX treatment in pSS patients.21
The B-cell repopulation seemed to recapitulate
B-cell ontogeny. The first B cells appearing in per-
ipheral blood are transitional type 1 (T1) B cells
(CD19þCD5þIgDþCD38þþ) and plasmablasts
(CD19þCD5–IgD–CD38þþ), followed by a further
increase of naive B cells migrating from the bone
marrow (BM). Memory B cells were early detected
during repopulation, first in peripheral blood and
only later in MSGs, although the number of
memory B cells remained relatively lower both in
PB and MSGs. Sequential MSG biopsies revealed
that B cells were absent in these glands for
12 months but they colonized the aﬀected glands
24 months after RTX treatment. Memory and T1 B
cells were the first B cells identified locally and, to
note, the GCs previously seen in the MSG were no
longer present after B-cell recovery. The sole diﬀer-
ence among the treated patients was in the timing
of B-cell reappearance and, in this regard, the
authors concluded that higher baseline serum
levels of B-cell activating factor (BAFF) inversely
correlated with the duration of B-cell depletion,
resulting in the reconstitution of the preexisting
abnormalities in PB.
BAFF and a proliferation-inducing ligand
(APRIL) are involved in B-cell survival and
humoral immune responses and play a critical
role in B-cell homeostasis; these molecules are
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produced by a variety of cells, mainly innate
immune cells, such as monocytes, macrophages,
dendritic cells and neutrophils and their expression
is increased in the presence of type I interferon
(IFN), type II IFN, other cytokines and Toll-like
receptor (TLR) ligands, as well as virus-infected
cells.22,23 Type I IFN and type I IFN-induced
genes and proteins are overexpressed in pSS,24
and pSS patients display elevated levels both of
BAFF and APRIL in serum and saliva, correlating
with the amount of immune infiltrates in MSGs,
serum immunoglobulin (Ig)G levels and autoanti-
body titers.11,25 BAFF and APRIL may bind both
the B-cell maturation antigen, expressed by plasma
cells and memory/GC B-cells, and the ‘‘transmem-
brane activator and calcium modulator and cyclo-
philin ligand interactor’’ (TACI), expressed on
CD27þ memory B cells, activated B cells and
plasma cells. Moreover, BAFF, but not APRIL,
binds BAFF receptor (BAFF-R), widely expressed
by human peripheral B cells.26
Abdulahad and colleagues confirmed that, fol-
lowing RTX treatment, circulating CD19þ B cells
started to reappear at week 24 and were partially or
fully reconstituted 36–48 weeks after treatment.27
The vast majority of the B cells that reappeared
had a phenotype of transitional B cells and, inter-
estingly, they did not derive from mature naive or
memory peripheral B cells that were not depleted
by RTX, but were newly generated B cells in the
BM. These authors found that the percentages and
the absolute numbers of Treg cells and eﬀector
T cells, as well as the ratio between eﬀector
T/Treg cells, did not significantly change after
RTX treatment.
Although diﬀerent dosing schedules for RTX
were used in diﬀerent studies, it can be concluded
that RTX produces eﬀective depletion of circulat-
ing B cells in pSS patients with similar kinetics and
B-cell subset reconstitution pattern, independent of
therapeutic strategies and diﬀerent dosages.21,27,28
RTX treatment might favorably modify the dis-
ease course in pSS by depleting pathogenic B-cell
clones, which may contribute both to autoimmun-
ity and lymphoma, resetting the B-cell repertoire.
However, the local persistence of clonally related
Ig-producing B cells in SGs and PB has been
reported despite RTX treatment, suggesting the
lack of a full restoration of the B-cell repertoire
to a pre-disease state.29,30 Indeed, persistence of
B-cell clones may explain the occurrence of relapses
after treatment, possibly triggered by additional
pathologic stimuli. In fact, it has been shown that
B-cell depletion therapy is followed by an increase
of serum BAFF levels, inversely correlated to the
B-cell number after repopulation, and highlighting
the role of BAFF in B-cell homeostasis both
in health and B-cell diseases. Of note, serum
APRIL levels seem not to be aﬀected by RTX.31
This datum may be explained by the notion that
APRIL receptors, TACI and B-cell maturation
agent, are selectively expressed by activated B
cells, whose number is generally low in pSS, and
by plasma cells, which are unaﬀected by RTX.
The B-cell depletion following RTX treatment
may modify the immunological micro-environment
of inflamed SGs, reducing antigen presentation
from B to T cells, and inducing apoptotic depletion
of other cell subsets, including mast cells. In this
setting, a reduction of glandular interleukin (IL)-
17 and IL-22 has been reported in pSS patients.32,33
Moreover, RTX is able to reduce serum levels
of diﬀerent molecules, including granulocyte-
macrophage colony-stimulating factor (GM-CSF),
IL-1Ra, IL-6, IL-10, IFNa, tumor necrosis factor
(TNF)a, CCL4 and CXCL9 and, of note, some of
these (GM-CSF, IL-6, IL-10, TNFa) may be pro-
duced by activated B cells.34 The levels of these
molecules significantly decreased after five to 12
weeks of RTX treatment, when B cells are virtually
absent in PB, suggesting that their decreased levels
may be an indirect eﬀects of B-cell depletion.
Finally, an in vitro system of pSS-SG epithelial
cells co-cultured with pSS lymphocytes provided
evidence that RTX treatment induces a significant
decrease of inflammation proteins, cytokines and
growth factors released by epithelial cells, as
shown by the decreased NF-kB DNA binding
activity in these cells, due to an upregulation of
the Raf-1 kinase inhibitor protein (RKIP).35
These data suggest a link between the downregula-
tion of NF-kB activity on the one hand, and the
inhibition of proinflammatory mediators observed
in vivo following RTX treatment on the other.
We recently concluded the first prospective, 120-
week follow-up study performed in a large cohort
of pSS patients receiving six courses of RTX as
first-line treatment for early active pSS, and MSG
biopsies were performed at baseline and at 120
weeks.36 As far as the extent of glandular inflam-
mation is concerned, our results confirmed the
aforementioned studies, showing a reduction of
lymphocytic foci and the Chisholm and Mason
score, in the majority of patients treated with
RTX. MSGs of these patients presented, after 120
weeks of treatment, a non-specific chronic sialade-
nitis pattern or a full restoration of glandular archi-
tecture, associated with the disappearance of GC
structures. Our study also provided additional
insights into the biologic eﬀects of RTX.
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We simultaneously evaluated the mRNA expres-
sion of a variety of cytokines and chemokines in
an attempt to provide evidence about the modula-
tion exerted by RTX on diﬀerent molecules.
The formation and maintenance of tertiary
lymphoid structures are critically dependent on
ectopic expression of lymphotoxins (LTa and
LTb), homeostatic chemokines such as CXCL13,
CXCL12, CCL19, CCL21 and their interactions
with specific receptors, CXCR5, CXCR4 and
CCR7, respectively.37,38 These interactions are
involved in B-cell deregulation, such as the prefer-
ential migration of CXCR4 and CXCR5 expressing
CD27þ memory B cells, the homing of CCR7-
expressing naive B cells into the inflamed salivary
glands, and the development of ectopic GC-like
structures as well as the peripheral B-cell
abnormalities.39–41
In this setting, we observed a consistent reduc-
tion at mRNA levels of CXCR4 and CXCR5, asso-
ciated with a parallel increase of the CXCL12 and
CXCL13 mRNAs, following anti-CD20 therapy.
Although Lta and Ltb were markedly reduced by
RTX, BAFF was not aﬀected by the biological
treatment. Finally, our study showed at the histo-
logical and molecular level the strong eﬀect of RTX
in dissolving the immunological organization of the
aﬀected tissues, which was not observed with
disease-modifying anti-rheumatic drug (DMARD)
therapy.36
Furthermore, we also showed that pSS patients
who develop GC-like infiltrates display not only a
diﬀerent clinical and serological profile, but also a
diﬀerent histological and glandular cytokine pro-
file, when compared to those without GC structures
or healthy controls.12
In conclusion, RTX treatment seems to interfere
with ectopic lymphoneogenesis not only by deplet-
ing B cells but also by tuning the delicate equilib-
rium between cells, molecules and receptors,
partially aﬀecting the pro-B-cell inflammatory
milieu.
Rituximab in pSS: clinical effects
RTX was first tested in several open-label studies in
pSS that suggested an improvement of fatigue,
sicca symptoms, glandular enlargement and extra-
glandular manifestations (Table 1). However, the
duration of the clinical eﬀects was rather variable
among the studies and these eﬀects partially over-
lapped PB B-cell depletion. Furthermore, retreat-
ment with RTX resulted in a clinical and
biological response comparable to the initial
treatment.42
The first open-label study enrolling a consistent
number of pSS patients with active disease was
published in 2007.19 Sixteen patients were followed
up for 36 weeks and RTX treatment induced a sig-
nificant improvement in fatigue, sicca symptoms
and joint involvement from week 12, still detectable
at week 36, and the treatment showed a significant
improvement in patients’ quality of life.58 Two sub-
sequent small, double-blind randomized studies
showed a certain eﬃcacy of RTX in patients both
with recent and active disease. The first, including
18 patients, showed an improvement of fatigue in
the RTX-treated group, after six months, without
any significant change in objective and subjective
sicca symptoms.48 The second study, comprising
30 patients, showed an improvement in sicca symp-
toms and extraglandular manifestations.50 Of note,
the strongest improvement was observed between
weeks 12–36, following RTX treatment, but at
week 48 the positive eﬀects were lost in all the
patients.
On this basis, two larger placebo-controlled,
double-blind studies were planned. Recently, only
the results of the French Tolerance and EﬃcAcy of
Rituximab in primary Sjo¨gren syndrome (TEARS)
study have been published.57 A total of 122 pSS
patients with recent-onset disease, with higher clin-
ical or serological disease activity, or alternatively,
extraglandular manifestations, were enrolled.
Although the study failed to reach the primary end-
point (improvement of at least 30mm on two of
four visual analog scales (VAS) exploring global
activity, fatigue, pain and dryness, between weeks
0 and 24), several secondary evaluation criteria
(dryness and fatigue scores, salivary flow rate,
laboratory response) were significantly improved
in patients treated with RTX. The authors con-
cluded that the eﬃcacy of RTX in pSS is not suﬃ-
cient to allow its prescription in a large population
of patients, but, at the same time, they pointed out
that this failure may be related to several limita-
tions regarding their trial. In fact, it is still debat-
able what might be the best outcome measure for
assessing the eﬃcacy of treatment in pSS and, since
this study included patients with and without sys-
temic manifestation, the EULAR Sjo¨gren’s
Syndrome Disease Activity Index (ESSDAI), vali-
dated to assess systemic pSS activity, might fail to
correctly assess patients with only a glandular
involvement. Moreover, the best interval for assess-
ing treatment eﬃcacy in pSS is unclear.
The Trial of anti-B-cell Therapy in Patients
with Primary Sjo¨gren’s Syndrome (TRACTISS)
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(a randomized, double-blind, placebo-controlled
clinical trial of anti-B-cell therapy in patients with
primary Sjo¨gren’s syndrome, ISRCTN65360827)
study in the United Kingdom (UK) completed the
enrollment in December 2013 and currently
includes 110 pSS patients.59 The study design was
intended to be closely aligned to that of the French
study, in order to allow subsequent data meta-
analysis.
As far as systemic involvement is concerned, an
RCT reported a reduction in extraglandular mani-
festations in patients treated with RTX, when com-
pared to placebo.50 Similar results were also
observed in uncontrolled studies, especially for
articular, vasculitic, pulmonary and neurological
involvement (Table 1). Among all pSS extragland-
ular manifestations, peripheral nervous system
(PNS) involvement is still a great challenge for
treatment. A concise report analyzed the eﬀect of
RTX in 17 pSS patients with PNS involvement.55
Three months after RTX treatment, 65% of
patients reported neurological improvement and
the benefits were maintained after nine months,
with a statistically significant improvement in the
ESSDAI.
Seror et al. reported a decrease in the daily dose
of corticosteroids in pSS patients with systemic
involvement after RTX treatment, highlighting
implications for reduction of the risk of steroid-
associated adverse events.46 Several studies
reported significant reductions in analytical param-
eters, such as erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), cryoglobulinemia,
RF, b2-microglobulin, and immunoglobulin
levels.19,28,43,44,46,48–50,55,57
We recently performed a prospective, multi-
center, follow-up study including 41 pSS patients
with early (ranging from six to 21 months) and
active disease receiving either RTX (19) or
DMARDs (22) plus a stable dose of prednisone.36
Disease activity was assessed by ESSDAI (arbitrar-
ily chosen" 6) and by values >50mm for two of
four VAS (0 to 100mm) such as: global disease
activity (including extraglandular manifestations),
pain, sicca symptoms and fatigue. The primary
endpoints were the evaluation of the safety of
RTX infusion and a significant variation in the
reduction of the ESSDAI in the RTX arm during
the study period of 120 weeks. Secondary endpoints
were measurement of salivary/lacrimal function,
subjective variables and biologic eﬀects of RTX in
MSGs, compared with patients treated with
DMARDs. Unlike previous studies, pSS patients
included in the RTX arm received six courses of
therapy (twice 1 g with an interval of 15 days,
every six months). In both treatment groups, no
adverse events were reported during the study and
the RTX infusions repeated over time were gener-
ally well tolerated. RTX treatment, already from
the second course of therapy, displayed a stronger
and significant eﬀect in decreasing the ESSDAI,
when compared with the DMARDs arm, and this
eﬀect was observed throughout the study period.
These data are partially due to a rapid and consist-
ent score reduction of constitutional, lymphaden-
opathy, glandular, articular and cutaneous
domains. The response curves for VAS global dis-
ease activity, VAS pain, VAS fatigue and physician
global assessment mirrored the pattern of ESSDAI.
These items significantly decreased in both groups,
and again the RTX arm showed a better perform-
ance when compared with the DMARDs popula-
tion. Such decrease was progressive up to week 72
and then reached a plateau until week 120.
At present, some concerns about the eﬃcacy of
RTX therapy in pSS still need to be addressed, for
example the wide range of immunological eﬀects
associated with B-cell depletion as well as the
reason underlying unresponsiveness to this com-
pound in some pSS patients. It may be speculated
that, at least in part, the contradictory results on
the real eﬃcacy of RTX in pSS may be related to
the lack of reliable clinimetric measures. Indeed,
some aspects of the disease including the definition
of early disease and activity may not be fully cov-
ered. Although pSS patients with early, active dis-
ease and extraglandular manifestations seem to be
most likely to benefit from RTX treatment, the lack
of such validated measures leads to a large clinical
heterogeneity in the study populations, which may
account for these conflicting results.60 In recent
years, several activity scores have been developed
in order both to catch the evolution of pSS and to
be ultimately used in clinical trials. The develop-
ment and validation of the objective ESSDAI
and patient-reported European League Against
Rheumatism (EULAR) Sjo¨gren’s Syndrome
Patient Reported Index (ESSPRI) oﬀered import-
ant tools for assessing clinical outcome and
responses to treatment.51,61,62 However, these
indexes include diﬀerent domains related to the
large variability of clinical and laboratory aspects
of the disease. It should be kept in mind that
although patients included in clinical trials display
the same scores, this does not reflect an overlapping
clinical and serological picture. In fact, an active
pSS patient with severe cytopenia may be diﬀerent
from an active pSS patient with arthritis or salivary
gland swelling. Taken together, it could be con-
sidered that the inclusion of diﬀerent clinical
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subsets of patients in the same study cohort may
introduce a critical bias in the understanding of the
real therapeutic eﬀect of RTX.
Taken into account that RTX eﬀect is transient
and disease relapses parallel B-cell repopulation in
the PB, pSS patients should be treated either by
monitoring the circulating B-cell number or at
fixed time-points.
As far as the safety of RTX treatment is con-
cerned, many studies reported that RTX is a safe
therapeutic strategy in pSS patients,19,28,46,52,55,56
and our data, although in a small cohort of
patients, suggest that this safety may still be main-
tained after six courses of repeated B-cell depletion
therapy.36
In our experience, RTX monotherapy was not
suﬃcient in the majority of pSS patients with
severe extraglandular manifestations, such as vas-
culitis, nephritis or polyneuropathy; conversely, we
obtained better results when we combined RTX
with long-term steroid treatment.36 Theoretically,
combining RTX with other biologics that be an
important future option, not only to decrease the
activity of disease, but also to control the mechan-
isms which seem to be involved in the flare after
RTX discontinuation. Our paper confirmed what
has already been observed by other authors con-
cerning the potential role of BAFF in B-cell
repopulation and in the occurrence of flares.
Hypothetically in pSS patients, after B-cell deple-
tion, targeting BAFF might interfere with the
mechanisms that lead to reactivation of the
disease.63
Conclusions
pSS encompasses several subsets of patients with
diﬀerent genetic background, pathophysiological
pathways, demographic features, and diﬀerent
responses to proposed therapies. Despite the
acknowledged role of B cells in pSS, mechanisms
leading to their abnormal activation and their
contribution to pSS pathogenesis are not fully
elucidated. In this setting, the development of
‘‘treat-to-target’’ strategies in pSS still needs a full
knowledge of the molecular mechanisms involved
in the disease manifestations, which may change
among patients.
Although in recent years important progress in
the understanding and management of pSS has
been reached, many concerns still remain regarding
the evaluation of the disease activity in this slowly
progressing disease, the discrimination between
activity and damage markers, and the clinical and
laboratory heterogeneity of pSS patients, thus lim-
iting our ability to understand the real eﬀects of
proposed therapies.
In the era of biologics, randomized, double-
blind, controlled trials represent the most powerful
tool to obtain comparable results and provide the
rationale to build solid therapeutic recommenda-
tions in pSS. In particular, in addition to CD20, a
variety of additional B-cell-associated surface mol-
ecules could be targeted for therapeutic purposes as
well as soluble mediators involved in B-cell activa-
tion and expansion. In this setting, the good results
observed in the published trials after RTX treat-
ment in pSS should represent the starting point to
develop evidence-based guidelines for the use of
biologic therapy in this disease.
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